Sign in

Trial result ·

Optimization of Anticoagulation Strategy During Cardiopulmonary Bypass in Neonates with Congenital Heart Disease: A Randomized Controlled Trial.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This trial looked at newborn babies with congenital heart disease. They had heart surgery using a heart-lung machine. Doctors give heparin to keep blood from clotting during this. The 76 babies were split by chance into groups of 38. One group got a first heparin dose of 600 U/kg. The other group got 400 U/kg. The 400 U/kg dose comes from adult care. The trial ran at one center.

What they found

The main test was a blood marker of clotting called F1+2. This marker rose less in the 600 U/kg group. More of these babies reached the target ACT level after the first dose. They had less chest drainage over 72 hours. They also spent less time on breathing machines. Blood, plasma and platelet needs did not clearly differ between groups. One baby in the 600 U/kg group died in hospital. No baby in the other group died.

What it means for patients

The authors link a 600 U/kg first dose to a smaller F1+2 rise. It was also linked to a stronger early ACT response. They say bigger studies are needed to show real benefit and safety.

Why it is not certain yet

The trial had only 76 babies, all at one center. Many other outcomes did not clearly differ between the groups. The authors say larger studies must still check benefit and safety. The abstract does not say how long the babies were followed.

Source

Optimization of Anticoagulation Strategy During Cardiopulmonary Bypass in Neonates with Congenital Heart Disease: A Randomized Controlled Trial.

PubMed · PMID 42899169

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Congenital heart disease publications